These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 22520084

  • 1. Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial.
    Sterling R, Lim J, Frith L, Snowise NG, Jacques L, Haumann B.
    Respir Med; 2012 Aug; 106(8):1110-5. PubMed ID: 22520084
    [Abstract] [Full Text] [Related]

  • 2. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 3. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 5. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J, Kang J, Lee SH, Wang C, Zhou X, Crawford J, Jacques L, Stone S.
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [Abstract] [Full Text] [Related]

  • 6. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G, Walker RR, Brooks J, Mehta R, Crater G.
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 8. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma.
    Bernstein DI, Bateman ED, Woodcock A, Toler WT, Forth R, Jacques L, Nunn C, O'Byrne PM.
    J Asthma; 2015 Oct; 52(10):1073-83. PubMed ID: 26291137
    [Abstract] [Full Text] [Related]

  • 9. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids.
    Lötvall J, Bateman ED, Bleecker ER, Busse WW, Woodcock A, Follows R, Lim J, Stone S, Jacques L, Haumann B.
    Eur Respir J; 2012 Sep; 40(3):570-9. PubMed ID: 22362859
    [Abstract] [Full Text] [Related]

  • 10. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER, Lötvall J, O'Byrne PM, Woodcock A, Busse WW, Kerwin EM, Forth R, Medley HV, Nunn C, Jacques L, Bateman ED.
    J Allergy Clin Immunol Pract; 2014 Sep; 2(5):553-61. PubMed ID: 25213048
    [Abstract] [Full Text] [Related]

  • 11. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 12. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.
    Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, Lettis S, Barnhart F, Haumann B.
    Chest; 2012 Jul; 142(1):119-127. PubMed ID: 22241764
    [Abstract] [Full Text] [Related]

  • 13. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing.
    Kempsford RD, Oliver A, Bal J, Tombs L, Quinn D.
    Respir Med; 2013 Dec; 107(12):1873-80. PubMed ID: 24200619
    [Abstract] [Full Text] [Related]

  • 14. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 15. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R, Norris V, Siederer S.
    Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H, Orozco S, Allen A.
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 18. Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy.
    Oliver AJ, Covar RA, Goldfrad CH, Klein RM, Pedersen SE, Sorkness CA, Tomkins SA, Villarán C, Grigg J.
    Respir Res; 2016 Apr 05; 17():37. PubMed ID: 27044326
    [Abstract] [Full Text] [Related]

  • 19. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D, Andersen L, Forth R, Jacques L, Yates L.
    J Asthma; 2018 Sep 05; 55(9):984-993. PubMed ID: 28961020
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A.
    Respir Med; 2014 Dec 05; 108(12):1752-60. PubMed ID: 25458157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.